Predicting patent challenges for small-molecule drugs: A cross-sectional study

Area of Science:

• Pharmaceutical economics
• Intellectual property law
• Drug market analysis

Background:

• High prescription drug costs in the U.S. are sustained by brand-name manufacturers' extended market exclusivity.
• Patent protection allows brand-name drugs a competition-free period, delaying generic entry.
• Understanding patent challenge predictors can inform policies to encourage earlier generic competition and reduce drug prices.

Purpose of the Study:

• To identify characteristics of brand-name drugs that predict patent challenges.
• To assess the role of market size and other drug attributes in predicting patent challenges.
• To inform policy development aimed at promoting timely generic competition and patient access.

Main Methods:

• Cross-sectional study of new small-molecule drugs approved by the FDA (2007-2018).
• Data sourced from IQVIA MIDAS, FDA's Orange Book, and FDA's Paragraph IV list.
• Predictive models (random forest, elastic net) used to assess patent challenges within one year of eligibility.

Main Results:

• 55% of studied drugs faced a patent challenge within the first year.
• Market value was the strongest predictor; larger markets had more challenges.
• Anti-infective drugs and those with fast-track approval were less likely to be challenged.

Conclusions:

• Generic competition timeliness varies significantly across drug markets.
• Predictive models can guide patent validity reviews and policy adjustments.
• Addressing market size disparities can help reduce brand-name drug prices and improve access.